A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• •Histological or cytological diagnosis of clinical Stage II-IIIB NSCLC of either non-squamous or squamous histology
• •Participants must have had complete resection of NSCLC
• •Prior treatment with neoadjuvant immune checkpoint inhibitor (pembrolizumab or nivolumab) in combination with histology-based platinum-based doublet chemotherapy
• •Participants must be randomized within 12 weeks of their surgery date
• •No evidence of disease recurrence or metastatic disease
• •Documentation of the presence of a KRAS G12C mutation